Orphan Drug Safety: FDA Asks How Much Pre-Approval Data Is Enough?

Agency's Advisory Committee for Pharmaceutical Science and Clinical Pharmacology will be asked to weigh pre-approval data requirements and discuss innovative approaches to boosting drug development for rare diseases at its March 2 meeting.